These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8815542)

  • 1. AIDS research. Receptor mutations help slow disease progression.
    Cohen J
    Science; 1996 Sep; 273(5283):1797-8. PubMed ID: 8815542
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.
    Dean M; Carrington M; Winkler C; Huttley GA; Smith MW; Allikmets R; Goedert JJ; Buchbinder SP; Vittinghoff E; Gomperts E; Donfield S; Vlahov D; Kaslow R; Saah A; Rinaldo C; Detels R; O'Brien SJ
    Science; 1996 Sep; 273(5283):1856-62. PubMed ID: 8791590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.
    Smith MW; Dean M; Carrington M; Winkler C; Huttley GA; Lomb DA; Goedert JJ; O'Brien TR; Jacobson LP; Kaslow R; Buchbinder S; Vittinghoff E; Vlahov D; Hoots K; Hilgartner MW; O'Brien SJ
    Science; 1997 Aug; 277(5328):959-65. PubMed ID: 9252328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphism in CX3CR1 and risk of HIV disease.
    McDermott DH; Colla JS; Kleeberger CA; Plankey M; Rosenberg PS; Smith ED; Zimmerman PA; Combadière C; Leitman SF; Kaslow RA; Goedert JJ; Berger EA; O'Brien TR; Murphy PM
    Science; 2000 Dec; 290(5499):2031. PubMed ID: 11187812
    [No Abstract]   [Full Text] [Related]  

  • 5. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1.
    Faure S; Meyer L; Costagliola D; Vaneensberghe C; Genin E; Autran B; Delfraissy JF; McDermott DH; Murphy PM; Debré P; Théodorou I; Combadière C
    Science; 2000 Mar; 287(5461):2274-7. PubMed ID: 10731151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV CCR5 resistance incomplete.
    Smith O
    Nat Med; 1997 Apr; 3(4):372-3. PubMed ID: 9095162
    [No Abstract]   [Full Text] [Related]  

  • 7. Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group.
    Garred P; Eugen-Olsen J; Iversen AK; Benfield TL; Svejgaard A; Hofmann B
    Lancet; 1997 Jun; 349(9069):1884. PubMed ID: 9217763
    [No Abstract]   [Full Text] [Related]  

  • 8. In search of AIDS-resistance genes.
    O'Brien SJ; Dean M
    Sci Am; 1997 Sep; 277(3):44-51. PubMed ID: 9274039
    [No Abstract]   [Full Text] [Related]  

  • 9. Natural resistance to HIV?
    Hill CM; Littman DR
    Nature; 1996 Aug; 382(6593):668-9. PubMed ID: 8751431
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic acceleration of AIDS progression by a promoter variant of CCR5.
    Martin MP; Dean M; Smith MW; Winkler C; Gerrard B; Michael NL; Lee B; Doms RW; Margolick J; Buchbinder S; Goedert JJ; O'Brien TR; Hilgartner MW; Vlahov D; O'Brien SJ; Carrington M
    Science; 1998 Dec; 282(5395):1907-11. PubMed ID: 9836644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression.
    Hendel H; Hénon N; Lebuanec H; Lachgar A; Poncelet H; Caillat-Zucman S; Winkler CA; Smith MW; Kenefic L; O'Brien S; Lu W; Andrieu JM; Zagury D; Schächter F; Rappaport J; Zagury JF
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):381-6. PubMed ID: 9833747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethics of AIDS study.
    Gomperts ED; Donfield SM
    Science; 1996 Dec; 274(5293):1596. PubMed ID: 8984621
    [No Abstract]   [Full Text] [Related]  

  • 13. CCR5-delta 32 gene deletion in HIV-1 infected patients.
    Wang B; Palasanthiran P; Zeigler J; Cunningham A; Saksena NK
    Lancet; 1997 Sep; 350(9079):742. PubMed ID: 9291932
    [No Abstract]   [Full Text] [Related]  

  • 14. CCR5-delta 32 gene deletion in HIV-1 infected patients.
    Smith MW; Dean M; Carrington M; Huttley GA; O'Brien SJ
    Lancet; 1997 Sep; 350(9079):741; author reply 742. PubMed ID: 9291930
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance to HIV-1 infection: it's in the genes.
    Fauci AS
    Nat Med; 1996 Sep; 2(9):966-7. PubMed ID: 8782446
    [No Abstract]   [Full Text] [Related]  

  • 16. CCR5-delta 32 gene deletion in HIV-1 infected patients.
    Michael NL; Louie LG; Sheppard HW
    Lancet; 1997 Sep; 350(9079):741-2. PubMed ID: 9291931
    [No Abstract]   [Full Text] [Related]  

  • 17. Contribution of cohort studies in understanding HIV pathogenesis: introduction of the GRIV cohort and preliminary results.
    Hendel H; Cho YY; Gauthier N; Rappaport J; Schächter F; Zagury JF
    Biomed Pharmacother; 1996; 50(10):480-7. PubMed ID: 9091061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes.
    Rappaport J; Cho YY; Hendel H; Schwartz EJ; Schachter F; Zagury JF
    Lancet; 1997 Mar; 349(9056):922-3. PubMed ID: 9093257
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group.
    Theodorou I; Meyer L; Magierowska M; Katlama C; Rouzioux C
    Lancet; 1997 Apr; 349(9060):1219-20. PubMed ID: 9130946
    [No Abstract]   [Full Text] [Related]  

  • 20. Mutant gene blocks HIV's entry into cells.
    NIAID AIDS Agenda; 1996 Sep; ():6. PubMed ID: 11363925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.